Drug Patents owned by Otsuka

1. List of Abilify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 10 days ago)

US8642600 OTSUKA Method of treating autism
Jan, 2022

(1 year, 10 days ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 10 days ago)

US6977257 OTSUKA Aripiprazole oral solution
Apr, 2022

(9 months ago)

US8642600

(Pediatric)

OTSUKA Method of treating autism
Jul, 2022

(6 months ago)

US6977257

(Pediatric)

OTSUKA Aripiprazole oral solution
Oct, 2022

(3 months ago)

US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(a month from now)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(a month from now)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(10 months from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 4 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(1 year, 10 months from now)

US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 11 months from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 11 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(3 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(4 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of schizophrenia; Treatment of irritability associated with autistic disorder; Treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's patent expiration?
More Information on Dosage

2. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 10 days ago)

US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 10 days ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(10 months from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 4 months from now)

US11476952 OTSUKA Pharma-informatics system
Apr, 2026

(3 years from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(3 years from now)

US7978064 OTSUKA Communication system with partial power source
Sep, 2026

(3 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(4 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(4 years from now)

US9119554 OTSUKA Pharma-informatics system
Dec, 2028

(5 years from now)

US9258035 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(6 years from now)

US9060708 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(6 years from now)

US8674825 OTSUKA Pharma-informatics system
Apr, 2029

(6 years from now)

US8956288 OTSUKA In-body power source having high surface area electrode
Jul, 2029

(6 years from now)

US10441194 OTSUKA Ingestible event marker systems
Jul, 2029

(6 years from now)

US8945005 OTSUKA Controlled activation ingestible identifier
Aug, 2029

(6 years from now)

US9433371 OTSUKA In-body device with virtual dipole signal amplification
Sep, 2029

(6 years from now)

US8718193 OTSUKA Active signal processing personal health signal receivers
Dec, 2029

(6 years from now)

US9149577 OTSUKA Body-associated receiver and method
Dec, 2029

(6 years from now)

US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(7 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(7 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(7 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(7 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(7 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(7 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(7 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(7 years from now)

US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(8 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(8 years from now)

US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(9 years from now)

US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
Oct, 2033

(10 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia; Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver; Method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Inqovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 7, 2025
Orphan Drug Exclusivity (ODE) Jul 7, 2027

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 07 July, 2020

Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine; Treatment of chronic myelomonocytic leukemia; Treatment of myelodysplastic syndrome

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Jynarque drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501730 OTSUKA Process for preparing benzazepine compounds or salts thereof
Sep, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905694 OTSUKA Pharmaceutical solid preparation comprising benzazepines and production method thereof
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 23, 2025

Drugs and Companies using TOLVAPTAN ingredient

Market Authorisation Date: 23 April, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JYNARQUE before it's patent expiration?
More Information on Dosage

5. List of Rexulti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7888362 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

USRE48059 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8349840 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

US9839637 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

US8618109 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 27, 2024

Drugs and Companies using BREXPIPRAZOLE ingredient

Market Authorisation Date: 10 July, 2015

Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia; Treatment of schizophrenia in adults and pediatric patients ages 13 years and older

Dosage: TABLET;ORAL

How can I launch a generic of REXULTI before it's patent expiration?
More Information on Dosage

6. List of Samsca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501730 OTSUKA Process for preparing benzazepine compounds or salts thereof
Sep, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905694 OTSUKA Pharmaceutical solid preparation comprising benzazepines and production method thereof
Apr, 2030

(7 years from now)

Drugs and Companies using TOLVAPTAN ingredient

Market Authorisation Date: 19 May, 2009

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SAMSCA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic